What to Know About Heart Failure When You Have Diabetes
In June of 2022, a report from the American Diabetes Association highlighted heart failure as “an underappreciated complication of diabetes.” According to that report, up to 22% of people with diabetes will develop heart failure, and the incidence of heart failure within the diabetes community is increasing.
“Heart failure is the most prevalent cardiovascular complication in people with diabetes,” says Dr. Rodica Pop-Busui, a professor of diabetes at the University of Michigan and president of medicine and science at the American Diabetes Association. “In the U.S. alone there are 37 million...
Source: TIME: Health - December 29, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
Trials Say Start ARNI in Hospital in HF,'Below Normal' LVEF Trials Say Start ARNI in Hospital in HF,'Below Normal' LVEF
Filling an evidence gap, a pooled analysis of patients with heart failure ' across the LVEF spectrum ' supports starting sacubitril-valsartan in the hospital.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
ARNI Again Shows Modest Benefits in HF With Mid-Range EF
(MedPage Today) -- Starting sacubitril/valsartan (Entresto) for recently decompensated heart failure with ejection fraction (EF) over 40% improved a key prognostic marker and, for those in the 40-60% range, clinical outcomes as well, the PARAGLIDE... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - June 23, 2023 Category: Urology & Nephrology Source Type: news
May 26 2023 This Week in Cardiology May 26 2023 This Week in Cardiology
An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week ' s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 26, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
ARNI Bests ARB to Reduce NT-proBNP in Stabilized HFpEF ARNI Bests ARB to Reduce NT-proBNP in Stabilized HFpEF
Sacubitril-valsartan led to a greater reduction of natriuretic peptides, less worsening renal function, but a higher rate of hypotension compared with valsartan in PARAGLIDE-HF.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 25, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
HC reserves order on Natco's plea over patent for Novartis drug
Natco has argued before Justice C Hari Shankar against the grant of patent by IPO to the pharmaceutical composition comprising combination of sacubitril + valsartan as a sodium salt complex of the Vymada. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 11, 2023 Category: Pharmaceuticals Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Frailty Poses No Limit to HFpEF Meds Frailty Poses No Limit to HFpEF Meds
Increased frailty of patients with heart failure with preserved ejection fraction should have no bearing on whether those patients receive sacubitril/valsartan, according to results of a data analysis.MDedge News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news
Sep 16 This Week in Cardiology Sep 16 This Week in Cardiology
The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Sacubitril/Valsartan Shows Cognitive Safety in Heart Failure Sacubitril/Valsartan Shows Cognitive Safety in Heart Failure
Patients with heart failure on sacubitril/valsartan had no signal of cognitive decline compared with controls in PERSPECTIVE, a prospective, multicenter study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 26, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
No Detrimental Impact on Cognition With Entresto for Heart Failure
(MedPage Today) -- BARCELONA -- Patients who were treated with sacubitril/valsartan (Entresto) for heart failure with moderately reduced or preserved left ventricular ejection fraction did not appear to experience worsening cognition function... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 26, 2022 Category: Urology & Nephrology Source Type: news
Pfizer Recalls Some Blood Pressure Drugs, Citing Cancer Risk
The move follows recalls of other medications found to have higher levels of potential carcinogens. (Source: NYT Health)
Source: NYT Health - March 23, 2022 Category: Consumer Health News Authors: Christina Jewett Tags: Drugs (Pharmaceuticals) Recalls and Bans of Products Cancer Food and Drug Administration Pfizer Inc your-feed-healthcare Accuretic nitrosamine valsartan Valisure ranitidine N-nitrosodimethylamine ndma metformin benzene Source Type: news
Dr Reddy's launches drug to treat high blood pressure, heart failure in US market
Citing IQVIA Health data, the company said the Diovan brand and generic market had US sales of approximately USD 150 million for the most recent 12 months ended October 2021, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2021 Category: Pharmaceuticals Source Type: news
Sacubitril/Valsartan May Alter Trajectory of Preclinical HFpEF Sacubitril/Valsartan May Alter Trajectory of Preclinical HFpEF
The combination was linked to greater changes in left atrial volume index on MRI than valsartan alone in the setting of reduced filling pressures in a phase 2 study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 24, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Sacubitril/Valsartan for HFpEF and Resistant Hypertension Sacubitril/Valsartan for HFpEF and Resistant Hypertension
A promising new study evaluates the combination of sacubitril/valsartan as a therapeutic strategy for HFpEF and resistant hypertension.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
